Table 2.
ABM dose range (mGy) | All hematological malignancies (n = 790) | Lymphoid malignancies (n = 578) | Myeloid malignancies and AL (n = 203) | Leukemia excluding CLL (n = 271) | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# | RR | 95% CI | # | RR | 95% CI | # | RR | 95% CI | # | RR | 95% CI | |||||
[0,5) | 125 | 1.00 | 91 | 1.00 | 34 | 1.00 | 38 | 1.00 | ||||||||
[5,10) | 171 | 1.10 | 0.87 | 1.39 | 120 | 1.07 | 0.81 | 1.42 | 47 | 1.08 | 0.69 | 1.71 | 43 | 0.79 | 0.51 | 1.24 |
[10,15) | 157 | 1.53 | 1.20 | 1.97 | 123 | 1.65 | 1.24 | 2.20 | 32 | 1.16 | 0.70 | 1.92 | 56 | 1.35 | 0.87 | 2.09 |
[15,25) | 165 | 1.40 | 1.09 | 1.80 | 121 | 1.41 | 1.05 | 1.90 | 42 | 1.31 | 0.80 | 2.15 | 66 | 1.21 | 0.78 | 1.89 |
[25,50) | 114 | 1.87 | 1.42 | 2.45 | 81 | 1.81 | 1.32 | 2.49 | 32 | 1.96 | 1.17 | 3.29 | 44 | 1.61 | 1.01 | 2.58 |
[50+] | 58 | 2.66 | 1.92 | 3.70 | 42 | 2.64 | 1.80 | 3.89 | 16 | 2.75 | 1.47 | 5.14 | 24 | 2.41 | 1.40 | 4.17 |
P for trend | 0.02 | 0.03 | 0.02 | 0.02 |
# | ERR/100 mGy | 95% CI | # | ERR/100 mGy | 95% CI | # | ERR/100 mGy | 95% CI | # | ERR/100 mGy | 95% CI | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
790 | 1.96 | 1.10 | 3.12 | 578 | 2.01 | 1.02 | 3.42 | 203 | 2.02 | 0.47 | 4.77 | 271 | 1.66 | 0.43 | 3.74 |
# | RR at 100 mGyb | 95% CI | # | RR at 100 mGy | 95% CI | # | RR at 100 mGy | 95% CI | # | RR at 100 mGy | 95% CI | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
790 | 2.96 | 2.10 | 4.12 | 578 | 3.01 | 2.02 | 4.42 | 203 | 3.02 | 1.47 | 5.77 | 271 | 2.66 | 1.43 | 4.74 |
Values are shown in RR, ERR/100 mGy and 95% CI.
#, number of cases.
Statistically significant values are shown in bold.
aNo analysis of histiocytic and dendritic cell malignancies or of unspecified malignancies were conducted because of the small number of cases (six and three, respectively).
bNote that the RR at 100 mGy is simply obtained by adding 1 to the ERR/100 mGy.